BE (Biological E) to become the first vaccine provider in India that can even be given to teenagers. WHO is ready to work with BE in India to increase vaccination services.
The WHO’s advisory committee on vaccine product development has come forward with India after reviewing several requests, which have expressed an interest in receiving mRNA (ribonucleic acid) technology.
Biological E success
Originally introduced last year, mRNA technology has been incorporated into Biological E’s long-term investment strategy. This new scientific breakthrough will facilitate BE’s ability to develop more vaccines in the future, which will be useful for everyone. BE will be better positioned to develop next-generation mRNA vaccines that are more broadly applicable and expand the availability of immunization worldwide due to collaboration with the World Health Organization.
“We can generate over 100 million doses per month to ensure enough supply,” Mahima Datla, managing director of Biological E, said during a press conference. “We can react to any increased demand,” she added. However, she did not explain why the company did not adjust the protein or medicinal compounds used in Corbevax for children and adults to make immunizations more similar across age groups.
According to a presentation given by Vikram Paradkar, executive vice president of Technical Operations at Biological E, the clinical investigations of Corbevax in children between the ages of 5 and 12 are nearing completion to the company.
In addition, he writes, “We are confident in our capacity to secure emergency use authorization (EUA) for that age range.” The interim report transmitted to the appropriate authority was also included in the report.
According to the World Health Organization, mRNA vaccines are used to prevent disease by instructing human cells on how to manufacture a protein, which, in turn, activates an immune response within the body against a specific disease (WHO).
A virus that enters the body will trigger a response by the immune system to defend against the virus itself. Unfortunately, the Covid-19 vaccine, which is based on the mRNA platform, is not available in India at present. However, with the help of mRNA technology, Pfizer-BioNTech and Moderna have developed two Covid-19 vaccines, which are currently being investigated in clinical studies.
The World Health Organization’s research and technology centre can enhance manufacturing capacity for other items, such as therapies, and handle other difficulties, such as cancer, if the Covid-19 scenario cannot be resolved fast. Biological E will benefit from collaborations with the Indian government, the World Health Organization, and other partners as it develops a plan to manufacture mRNA vaccines as quickly as feasible, with the requisite resources and experience in place.
Reports and Investment
By 30th March, more than 84.4% of adults in India had received the Covid-19 vaccination, according to government data. But, according to a government report given to the Rajya Sabha on Tuesday night, there are still 2.6 million people who have not yet taken even a single vaccine dosage.
In total, 79.28 crore (84.4%) beneficiaries aged 18 years and above had obtained both dosages of Covid-19 immunization as of 30 March 2022, and 167.14 crore doses (97% of the total dose administered) had been administrated completely for free to eligible beneficiaries (aged 18 years or above) under the National Covid-19 vaccination program. However, according to the World Health Organization, a projected 2.6 crore (2.8%) of eligible recipients over the age of 18 have not received even one single dose of vaccine.
Following WHO’s investment in mRNA technology since last year, the company will be able to develop next-generation mRNA vaccines that will be more suitable for global use and, as a consequence of its relationship with the World Health Organization, will expand vaccine availability worldwide.
With the help of WHO, BE in India will provide the vaccines to the people of India at a very low price and will help the people to get vaccinated easily. Furthermore, with the advancement in technology, BE has made it possible to keep immunizing teenagers from coronavirus disease and help parents safely send their children to school. Also, with the low rates and large production, BE is planning to reach as many people as possible worldwide.